320 related articles for article (PubMed ID: 31511361)
1. AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
Chow BSM; Kocan M; Shen M; Wang Y; Han L; Chew JY; Wang C; Bosnyak S; Mirabito-Colafella KM; Barsha G; Wigg B; Johnstone EKM; Hossain MA; Pfleger KDG; Denton KM; Widdop RE; Summers RJ; Bathgate RAD; Hewitson TD; Samuel CS
J Am Soc Nephrol; 2019 Nov; 30(11):2191-2207. PubMed ID: 31511361
[TBL] [Abstract][Full Text] [Related]
2. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
3. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
4. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
[No Abstract] [Full Text] [Related]
5. β-Arrestin-biased AT1R stimulation promotes extracellular matrix synthesis in renal fibrosis.
Wang Y; Huang J; Liu X; Niu Y; Zhao L; Yu Y; Zhou L; Lu L; Yu C
Am J Physiol Renal Physiol; 2017 Jul; 313(1):F1-F8. PubMed ID: 28274926
[TBL] [Abstract][Full Text] [Related]
6. Reversal of Aortic Enlargement Induced by Increased Biomechanical Forces Requires AT1R Inhibition in Conjunction With AT2R Activation.
Zhou Z; Peters AM; Wang S; Janda A; Chen J; Zhou P; Arthur E; Kwartler CS; Milewicz DM
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):459-466. PubMed ID: 30602301
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Kusunoki H; Taniyama Y; Rakugi H; Morishita R
J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
[TBL] [Abstract][Full Text] [Related]
8. Relaxin Attenuates Organ Fibrosis
Barsha G; Walton SL; Kwok E; Mirabito Colafella KM; Pinar AA; Hilliard Krause LM; Gaspari TA; Widdop RE; Samuel CS; Denton KM
Kidney360; 2021 Nov; 2(11):1781-1792. PubMed ID: 35373008
[TBL] [Abstract][Full Text] [Related]
9. Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade.
Moudgil R; Musat-Marcu S; Xu Y; Kumar D; Jugdutt BI
Can J Cardiol; 2002 Aug; 18(8):873-83. PubMed ID: 12215750
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Chow BS; Koulis C; Krishnaswamy P; Steckelings UM; Unger T; Cooper ME; Jandeleit-Dahm KA; Allen TJ
Diabetologia; 2016 Aug; 59(8):1778-90. PubMed ID: 27168137
[TBL] [Abstract][Full Text] [Related]
11. Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.
Callera GE; Antunes TT; Correa JW; Moorman D; Gutsol A; He Y; Cat AN; Briones AM; Montezano AC; Burns KD; Touyz RM
Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27612496
[TBL] [Abstract][Full Text] [Related]
12. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade.
Widdop RE; Matrougui K; Levy BI; Henrion D
Hypertension; 2002 Oct; 40(4):516-20. PubMed ID: 12364356
[TBL] [Abstract][Full Text] [Related]
13. Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
Ager EI; Wen SW; Chan J; Chong WW; Neo JH; Christophi C
BMC Cancer; 2011 Jun; 11():274. PubMed ID: 21703011
[TBL] [Abstract][Full Text] [Related]
14. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists.
Hu X; Myhr C; Huang Z; Xiao J; Barnaeva E; Ho BA; Agoulnik IU; Ferrer M; Marugan JJ; Southall N; Agoulnik AI
Biochemistry; 2016 Mar; 55(12):1772-83. PubMed ID: 26866459
[TBL] [Abstract][Full Text] [Related]
15. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors.
Bosnyak S; Jones ES; Christopoulos A; Aguilar MI; Thomas WG; Widdop RE
Clin Sci (Lond); 2011 Oct; 121(7):297-303. PubMed ID: 21542804
[TBL] [Abstract][Full Text] [Related]
16. AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat.
Jugdutt BI; Menon V
Mol Cell Biochem; 2004 Jul; 262(1-2):203-14. PubMed ID: 15532725
[TBL] [Abstract][Full Text] [Related]
17. Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK-5/Smad2/3 signaling pathway.
Wu XP; Wang HJ; Wang YL; Shen HR; Tan YZ
Exp Cell Res; 2018 Jan; 362(1):17-27. PubMed ID: 28987540
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation.
Kurihara T; Ozawa Y; Shinoda K; Nagai N; Inoue M; Oike Y; Tsubota K; Ishida S; Okano H
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5545-52. PubMed ID: 17122147
[TBL] [Abstract][Full Text] [Related]
19. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.
Hossain MA; Man BC; Zhao C; Xu Q; Du XJ; Wade JD; Samuel CS
Biochemistry; 2011 Mar; 50(8):1368-75. PubMed ID: 21229994
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous inflammation differentially regulates the expression and function of Angiotensin-II types 1 and 2 receptors in rat primary sensory neurons.
Benitez SG; Seltzer AM; Messina DN; Foscolo MR; Patterson SI; Acosta CG
J Neurochem; 2020 Mar; 152(6):675-696. PubMed ID: 31386177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
